Teva Pharmaceutical Industries Limited

Teva Pharmaceuticals International Gmbh

Ratiopharm Gmbh

Julia Hrakovsky

Ruth Tenengauzer

Judith Aronhime

Wolfgang Albrecht

Claude Singer

Tamar Nidam

Marioara Mendelovici

Vinod Kumar Kansal

Brijnath P Chaurasia

Marina Ratkaj

Joseph Schwarz

Richard Guserle

Dirk Schenk

Jens Geier

Michael Pesachovich

Ralph Stefan

Naveen C Srivastav

Claudia Lauer

Ashish Tripathi

Ramkaran Prajapati

Pavan V Kumar

Hans-Juergen Mika

Alla Ioffe

Siva Rama Krishna Muppalla

Eleonora Moin-Kotliar

Michal Agami

Roman Safonov

Ronen Borochovitch

Lev Khondo

Tania Lessen

Mathi Mathivanan

Siva Muppalla

Brijnath Chaurasia

Naveen Srivastav

Pavan Kumar

Grigory Bogomolny

Yehudit Dolitsky

The present disclosure encompasses solid state forms of Sofosbuvir, processes for their production, and pharmaceutical compositions thereof.

Solid state forms of sofosbuvir

The present invention provides a process for preparing a pharmaceutical composition of fingolimod comprising: (i) obtaining a intimate admixture comprising fingolimod or a pharmaceutically acceptable salt thereof, and at least one surfactant (wetting agent), e.g., an intimate admixture of the fingolimod and the at least one surfactant, and (ii) optionally combining the intimate admixture from step (i) with one or more excipients. Also provided are pharmaceutical compositions and dosage forms obtainable by the process, uses of the pharmaceutical compositions and dosage forms, and methods of treating appropriate diseases with the pharmaceutical compositions or dosage forms.

Process for preparing pharmaceutical compositions of fingolimod

The invention encompasses wet granulation pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the wet granulation pharmaceutical composition.

Wet formulations of aripiprazole

The present invention provides pharmaceutical compositions comprising aliphatic amine polymers such as for example Sevelamer HCl as the active pharmaceutical ingredient, wherein the aliphatica amine polymers are spray granulated. The present invention further provides methods of preparing stable pharmaceutical compositions of aliphatic amine polymers such as for example Sevelamer HCl, preferably in tablets dosage forms.

Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture

The present invention encompasses a method of evaluating pharmaceutical compositions of meloxicam whereby one can correlate in vitro properties to in vivo properties, and pharmaceutical compositions developed using the method.

Pharmaceutical compositions comprising meloxicam and methods of their preparation

Provided are processes for preparation of crystalline sertraline hydrochloride Form II substantilly free of other polymorphic forms of sertraline hydrochloride, preferably on an industrial scale.

Processes for preparation of polymorphic form II of sertraline hydrochloride

Compositions and methods of stabilizing azithromycin compositions are described. Stabilized azithromycin compositions comprise an intimate admixture of azithromycin and a stabilizing-effective amount of an antioxidant to improve the resistance of the azithromycin to degradation. Coprecipitation or co-milling of azithromycin and an antioxidant are particularly preferred means of achieving an intimate admixture. Pharmaceutical formulations comprising a stabilized azithromycin composition and methods of making such formulations are also described.

Stabilized azithromycin compositions

Growing community of inventors

Rosh Ha-Ayin, Israel

Julia Hrakovsky